Skip to main content

Table 2 Clinicopathological features for intrinsic subtypes

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

  All cases ER/PR+, HER2- ER/PR+, HER2+ HER2 type Basal-like Unclassified P
Cases (%) 471 (100) 306 (65.0) 41 (8.7) 59 (12.5) 37 (7.9) 28 (5.9)  
Mean age at diagnosis (years) 57.3 ±12.6 57.1 ±12.9 55.2 ±8.7 58.5 ±12.0 57.6 ±13.7 59.9 ±13.8 0.57 (Analysis of variance)
Menopausal status at diagnosis 0.8
(Fisher)
Premenopausal 169 (35.9) 115 (37.6) 15 (36.6) 18 (30.5) 11 (29.7) 10 (35.7)
Postmenopausal 302 (64.1) 191 (62.4) 26 (63.4) 41 (69.5) 26 (70.3) 18 (64.3)
Stage 0.1 (Cochran-Mantel-Haenszel)
0 57 (12.1) 41 (13.4) 2 (4.9) 8 (13.6) 1 (2.7) 5 (17.9)
I 138 (29.3) 97 (31.7) 16 (39.0) 9 (15.2) 9 (24.3) 7 (25.0)
IIA, IIB 232 (49.3) 139 (45.4) 19 (46.3) 34 (57.6) 24 (64.9) 16 (57.1)
IIIA, IIIB, IIIC 40 (8.5) 27 (8.8) 4 (9.8) 7 (11.9) 2 (5.4) 0 (0)
IV 4 (0.8) 2 (0.7) 0 (0) 1 (1.7) 1 (2.7) 0 (0)
Histological type <0.01 (Fisher)
Papillotubular carcinoma 94 (20.0) 49 (16.0) 13 (31.7) 18 (30.5) 7 (18.9) 7 (28.0)
Solid-tubular carcinoma 83 (17.6) 36 (11.8) 6 (14.6) 14 (23.7) 23 (62.2) 4 (14.3)
Scirrhous carcinoma 194 (41.2) 145 (47.4) 19 (46.4) 18 (30.5) 3 (8.1) 9 (32.1)
Noninvasive carcinoma, Paget’s disease 65 (13.8) 49 (16.0) 2 (4.9) 8 (13.6) 1 (2.7) 5 (17.9)
Others 35 (7.4) 27 (8.8) 1 (2.4) 1 (1.7) 3 (8.1) 3 (10.7)
Histological type (invasive ductal carcinoma only) <0.01 (Fisher)
Papillotubular carcinoma 94 (25.3) 49 (21.3) 13 (34.2) 18 (36.0) 7 (21.2) 7 (35.0)
Solid-tubular carcinoma 83 (22.4) 36 (15.7) 6 (15.8) 14 (28.0) 23 (69.7) 4 (20.0)
Scirrhous carcinoma 194 (52.3) 145 (63.0) 19 (50.0) 18 (36.0) 3 (9.1) 9 (45.0)
Lymphatic invasion 0.31 (Fisher)
Positive 269 (57.1) 169 (55.2) 27 (65.9) 31 (52.5) 26 (70.3) 16 (57.1)
Negative 202 (42.9) 137 (44.8) 14 (34.1) 28 (47.5) 11 (29.7) 12 (42.9)
Blood vessel invasion 0.19 (Fisher)
Positive 33 (7.0) 18 (5.9) 4 (9.8) 8 (13.6) 1 (2.7) 2 (7.1)
Negative 438 (93.0) 288 (94.1) 37 (90.2) 51 (86.4) 36 (97.3) 26 (92.9)
Lymph node metastases (Level I) 0.62 (Fisher)
Positive 88 (18.7) 59 (19.3) 7 (17.1) 14 (23.7) 5 (13.5) 3 (10.7)
Negative 383 (81.3) 247 (80.7) 34 (82.9) 45 (76.3) 32 (86.5) 25 (89.3)
Lymph node metastases (Level II) 0.97 (Fisher)
Positive 30 (6.4) 19 (6.2) 3 (7.3) 4 (6.8) 2 (5.4) 2 (7.1)
Negative 441 (93.6) 287 (93.8) 38 (92.7) 55 (93.2) 35 (94.6) 26 (92.9)
Lymph node metastases (Level III) 0.56 (Fisher)
Positive 16 (3.4) 11 (3.6) 3 (7.3) 1 (1.7) 1 (2.7) 0 (0)
Negative 455 (96.6) 295 (96.4) 38 (92.7) 58 (98.3) 36 (97.3) 28 (100)
  Invasive carcinoma cases ER /PR +, HER2- ER/PR +, HER2+ HER2 type Basal- like Unclassified P
Cases (%) 406 (100%) 257 (63.3%) 39 (9.6%) 51 (12.6%) 36 (8.9%) 23 (5.7%)  
Tumor size 0.54 (Fisher)
≤ 2.0 cm 272 (67.0) 179 (69.6) 24 (61.5) 32 (62.7) 24 (66.7) 13 (56.5)
>2.0 cm 134 (33.0) 78 (30.4) 15 (38.5) 19 (37.3) 12 (33.3) 10 (43.5)
Histological grade (total score) <0.01 (Fisher)
Grade I 200 (49.3) 148 (57.6) 21 (53.8) 14 (27.4) 5 (13.9) 12 (52.2)
Grade II or III 201 (49.5) 106 (41.2) 18 (46.2) 36 (70.6) 31 (86.1) 10 (43.5)
Unknown 5 (1.2) 3 (1.2) 0 (0) 1 (2.0) 0 (0) 1 (4.3)